Pompe disease

Pharma

Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia

Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.

Angus Liu May 17, 2024 8:30am

Amicus scores $430M financing deal with asset manager Blackstone

Oct 2, 2023 4:16pm

FDA OKs Amicus Pompe combo, setting up market battle with Sanofi

Sep 28, 2023 3:15pm

Traffic light go start restart green light

Amicus' Pompe approval portends a showdown with Sanofi

Mar 28, 2023 10:25am

Eisai, GSK, Daiichi Sankyo—Fierce Pharma Asia

Nov 4, 2022 9:00am

The FDA blamed COVID for delaying its review of Amicus' drug

Oct 31, 2022 3:08pm